8-K/ALeadership Changes

REGENERON PHARMACEUTICALS, INC. 8-K/A Report, Executive Changes (Jan 24, 2012)

Filed January 24, 2012For Securities:REGN

Summary

This filing is an amendment to a previous 8-K report filed by Regeneron Pharmaceuticals, Inc. (REGN) on November 22, 2011. The amendment clarifies information regarding board committee appointments for Dr. Marc Tessier-Lavigne, who was elected as a director on November 18, 2011. The original report stated that committee assignments were not yet determined at the time of filing. Investors should note that the sole purpose of this amendment is to disclose that, as of January 20, 2012, Dr. Tessier-Lavigne was appointed to both the Compensation Committee and the Technology Committee of Regeneron's Board of Directors. This information is a follow-up to the initial director election and provides completeness to the board composition and committee structure.

Key Highlights

  • 1Amendment to a previous 8-K filing from November 22, 2011.
  • 2Clarifies board committee appointments for newly elected director, Dr. Marc Tessier-Lavigne.
  • 3Dr. Tessier-Lavigne was elected to the Board of Directors on November 18, 2011.
  • 4The amendment was filed to disclose previously undetermined committee assignments.
  • 5As of January 20, 2012, Dr. Tessier-Lavigne was appointed to the Compensation Committee.
  • 6As of January 20, 2012, Dr. Tessier-Lavigne was also appointed to the Technology Committee.

Frequently Asked Questions

The primary purpose of this amended 8-K filing is to provide an update on the board committee appointments for Dr. Marc Tessier-Lavigne, who was elected as a director in November 2011. These specific committee assignments were not determined at the time of the original 8-K filing.

Dr. Marc Tessier-Lavigne's board committee assignments were finalized on January 20, 2012.

Dr. Marc Tessier-Lavigne was appointed to the Compensation Committee and the Technology Committee of Regeneron's Board of Directors.

No, this filing is purely administrative and serves to amend a previous report by disclosing information about board committee appointments. It does not contain information regarding financial performance, strategic changes, or any material business events.